HOOKIPA Pharma Inc. HOOK
Set alert
As of Jul 17, 9:30 AM ET
52-week range unavailable
- YTD
- +28.78%
- 1 year
- -19.01%
- Open
- 1.15
- Prev close
- 1.15
- Mkt cap
- 24.47M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.15
- High
- 1.15
- Forward P/E
- -0.37
- Beta
- 0.83
- Short ratio
- 1.08
- Inst. own
- 37.16%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 3.09
- 200-d avg
- 5.66
- 1y target
- 23.50
3M chart
Signals (9)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Jun 26, 2026 | 4 months ago |
| SMA: Bearish | May 28, 2026 | 5 months ago |
| SMA: Bearish | May 28, 2026 | 5 months ago |
| SMA: Bullish | May 26, 2026 | 5 months ago |
| MACD: Sell Signal | May 13, 2026 | 5 months ago |
| MACD: Buy Signal | May 1, 2026 | 6 months ago |
| SMA: Bullish | Apr 28, 2026 | 6 months ago |
| SMA: Bearish | Apr 23, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 21, 2026 | 6 months ago |
Key statistics
- Market cap
- 24.47M
- Enterprise value
- -36.09M
- Trailing P/E
- 0.00
- Forward P/E
- -0.37
- PEG ratio
- 0.00
- Price / sales
- 0.47
- Price / book
- 0.27
- EPS (TTM)
- -3.67
- Beta
- 0.83
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -93.16%
- Revenue (TTM)
- 52.16M
- Revenue growth
- -51.80%
- Free cash flow
- -46.05M
- Total cash
- 77.15M
- Total debt
- 4.90M
- Return on equity
- -48.99%
- Shares outstanding
- 9.66M
- Short % of float
- 0.47%
- 50-day average
- 3.09
- 200-day average
- 5.66
Analyst view
Consensus: buy
- Target (low)
- 7.00
- Target (mean)
- 23.50
- Target (high)
- 40.00
- Strong buy1
- Buy1
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.97.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -1.10 | — | — |
| Aug 8, 2024 | Jun 1, 2024 | -1.44 | -1.52 | -0.08 | -5.56% |
| May 9, 2024 | Mar 1, 2024 | -1.20 | 1.20 | +2.40 | +200.00% |
| Mar 22, 2024 | Dec 1, 2023 | -2.00 | -1.10 | +0.90 | +45.00% |
| Nov 9, 2023 | Sep 1, 2023 | -2.30 | -1.70 | +0.60 | +26.09% |
| Aug 10, 2023 | Jun 1, 2023 | -2.10 | -2.20 | -0.10 | -4.76% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 20, 2024 | RBC Capital | down | Outperform | Sector Perform |
| Nov 21, 2024 | JMP Securities | main | Market Outperform | Market Outperform |
| Nov 15, 2024 | RBC Capital | main | Outperform | Outperform |
| Aug 9, 2024 | JMP Securities | main | Market Outperform | Market Outperform |
| Jul 26, 2024 | JMP Securities | main | Market Outperform | Market Outperform |
| Jun 5, 2024 | HC Wainwright & Co. | main | Buy | Buy |
About HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-200 for the treatment of pembrolizumab which is in Phase 2 of clinical trial; HB-700, a preclinical development for treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers. Its lead product candidates are HB-400 for the treatment of Hepatitis B which is in Phase I of clinical trial and HB-500 for the treatment of HIV which is in Phase I of clinical trial. The company's preclinical stage products include HB-300 program for prostate cancer. It has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- hookipapharma.com
News
- HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics
- HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead
- HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)
- HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)
- Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPA
- HOOKIPA Pharma Inc - FORM 8 (OPD)
- HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements
- Gilead backs proposed Poolbeg Pharma's proposed tie-up with HOOKIPA
Your note
Sign in to keep a note on HOOK — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALDAG JORN | Chief Executive Officer | Purchase | Jul 10, 2023 | 71,952 |
| COELHO MARY THERESA | Chief Financial Officer | Stock Award(Grant) | Jul 21, 2024 | 69,875 |
| KANDERA REINHARD | Chief Financial Officer | Purchase | Aug 20, 2023 | 43,092 |
| PETERS MALTE | Chief Executive Officer | Stock Award(Grant) | Jul 21, 2024 | 108,695 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Baker Bros. Advisors, LP | 8.42% | 812,814 | 1.65M | Sep 29, 2024 |
| EcoR1 Capital, LLC | 5.92% | 571,727 | 1.16M | Sep 29, 2024 |
| Siren, L.L.C. | 5.87% | 566,640 | 1.15M | Sep 29, 2024 |
| Knoll Capital Management, LLC | 5.71% | 551,738 | 1.12M | Sep 29, 2024 |
| FMR, LLC | 3.54% | 341,476 | 693.20K | Sep 29, 2024 |
| Vanguard Group Inc | 2.21% | 213,222 | 432.84K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.46% | 140,788 | 285.80K | Sep 29, 2024 |
| Variable Insurance Products Fund-Growth Portfolio | 1.05% | 101,448 | 205.94K | Oct 30, 2024 |
| Fidelity Capital Appreciation Fund | 0.95% | 91,620 | 185.99K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.72% | 69,843 | 141.78K | Sep 29, 2024 |
| Fidelity Advisor Equity Growth Fund | 0.69% | 66,861 | 135.73K | Oct 30, 2024 |
| Fidelity Growth Discovery Fund | 0.47% | 45,078 | 91.51K | Oct 30, 2024 |